Literature DB >> 458555

Role of concentration-dependent plasma protein binding in disopyramide disposition.

P J Meffin, E W Robert, R A Winkle, S Harapat, F A Peters, D C Harrison.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 458555     DOI： 10.1007/bf01059439

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN： 0090-466X


× No keyword cloud information.
  17 in total

1.  The pharmacokinetics of Norpace.

Authors:  A Karim
Journal:  Angiology       Date:  1975-01       Impact factor: 3.619

2.  Linear pharmacokinetic equations allowing direct calculation of many needed pharmacokinetic parameters from the coefficients and exponents of polyexponential equations which have been fitted to the data.

Authors:  J G Wagner
Journal:  J Pharmacokinet Biopharm       Date:  1976-10

3.  The pharmacokinetics of disopyramide following myocardial infarction with special reference to oral and intravenous dose regimens.

Authors:  J W Ward; G R Kinghorn
Journal:  J Int Med Res       Date:  1976       Impact factor: 1.671

4.  Correlation of disopyramide pharmacokinetics with efficacy in ventricular tachyarrhythmia.

Authors:  R E Rangno; W Warnica; R I Ogilvie; J Kreeft; E Bridger
Journal:  J Int Med Res       Date:  1976       Impact factor: 1.671

5.  Pharmacokinetics of the antiarrhythmic disopyramide in healthy humans.

Authors:  P H Hinderling; E R Garrett
Journal:  J Pharmacokinet Biopharm       Date:  1976-06

6.  The effects of urine pH and plasma protein binding on the renal clearance of disopyramide.

Authors:  J L Cunningham; D D Shen; I Shudo; D L Azarnoff
Journal:  Clin Pharmacokinet       Date:  1977 Sep-Oct       Impact factor: 6.447

7.  Disopyramide phosphate: pharmacokinetic and pharmacologic relationships of a new antiarrhythmic agent.

Authors:  R E Ranney; R R Dean; A Karim; F M Radzialowski
Journal:  Arch Int Pharmacodyn Ther       Date:  1971-05

8.  Binding of anilide-type local anesthetics in human plasma. I. Relationships between binding, physicochemical properties, and anesthetic activity.

Authors:  G T Tucker; R N Boyes; P O Bridenbaugh; D C Moore
Journal:  Anesthesiology       Date:  1970-09       Impact factor: 7.892

9.  Anti-arrhythmic and haemodynamic effects of intravenous and oral disopyramide in patients with ventricular arrhythmia.

Authors:  J Hulting; G Rosenhamer
Journal:  J Int Med Res       Date:  1976       Impact factor: 1.671

10.  Observations on the antirheumatic and physiologic effects of phenylbutazone (butazolidin) and some comparisons with cortisone.

Authors:  B B BRODIE; E W LOWMAN; J J BURNS; P R LEE; T CHENKIN; A GOLDMAN; M WEINER; J M STEELE
Journal:  Am J Med       Date:  1954-02       Impact factor: 4.965
View more
  51 in total

Review 1.  Therapeutic drug monitoring of antiarrhythmic drugs.

Authors:  Gesche Jürgens; Niels A Graudal; Jens P Kampmann
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 2.  Nonlinear pharmacokinetics: clinical Implications.

Authors:  T M Ludden
Journal:  Clin Pharmacokinet       Date:  1991-06       Impact factor: 6.447

Review 3.  Therapeutic drug monitoring: antiarrhythmic drugs.

Authors:  T J Campbell; K M Williams
Journal:  Br J Clin Pharmacol       Date:  1998-10       Impact factor: 4.335

Review 4.  Plasma protein binding of drugs in pregnancy and in neonates.

Authors:  L J Notarianni
Journal:  Clin Pharmacokinet       Date:  1990-01       Impact factor: 6.447

Review 5.  Adverse effects of class I antiarrhythmic drugs.

Authors:  J Caron; C Libersa
Journal:  Drug Saf       Date:  1997-07       Impact factor: 5.606

6.  Relationship between alpha 1-acid glycoprotein and distribution of disopyramide and mono-N-dealkyldisopyramide in whole blood.

Authors:  J E Bredesen; P Kierulf
Journal:  Br J Clin Pharmacol       Date:  1986-09       Impact factor: 4.335

7.  Plasma concentrations and protein binding of disopyramide and mono-N-dealkyldisopyramide during chronic oral disopyramide therapy.

Authors:  M L Aitio
Journal:  Br J Clin Pharmacol       Date:  1981-04       Impact factor: 4.335

8.  Effect of concentration-dependent binding to plasma proteins on the pharmacokinetics and pharmacodynamics of disopyramide.

Authors:  K M Giacomini; T F Blaschke
Journal:  Clin Pharmacokinet       Date:  1984-01       Impact factor: 6.447

Review 9.  Clinical pharmacokinetics of disopyramide.

Authors:  L A Siddoway; R L Woosley
Journal:  Clin Pharmacokinet       Date:  1986 May-Jun       Impact factor: 6.447

10.  The effect of saturable binding to plasma proteins on the pharmacokinetic properties of disopyramide.

Authors:  K M Giacomini; S E Swezey; K Turner-Tamiyasu; T F Blaschke
Journal:  J Pharmacokinet Biopharm       Date:  1982-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.